Exchange Surveillance
- ASM Stage IVLong Term Additional Surveillance Measure (LTASM) - Stage IV
Price band ± 5% · narrower than the standard 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Solan, Himachal Pradesh
- Chairman
- Sushil Suri
- CEO & MD
- Sushil Suri
- Registrar
- Mas Services Ltd.
- Exchange
- NSE
- ISIN
- INE083A01026
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Morepen Laboratories Ltd today?
Morepen Laboratories Ltd (MOREPENLAB) is trading at ₹123.54. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is MOREPENLAB’s P/E ratio versus the sector?
MOREPENLAB trades at a P/E of 60.3. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is MOREPENLAB’s dividend yield?
MOREPENLAB has a dividend yield of 0.16%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is MOREPENLAB’s 52-week high and low?
MOREPENLAB has traded between ₹33.05 and ₹150.7 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has a market capitalisation of ₹6,704 crore.
▶What is MOREPENLAB’s return on equity?
MOREPENLAB reports a return on equity of 5.3%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are MOREPENLAB’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is MOREPENLAB’s promoter holding?
Promoters hold 35.66% of MOREPENLAB. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include MOREPENLAB?
Index membership is listed in the Context block on this page, along with the weight MOREPENLAB carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Morepen Laboratories Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from MOREPENLAB’s own numbers. The judgement is yours.
MOREPENLAB at a glance
Morepen Laboratories Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Morepen Laboratories Ltd (MOREPENLAB) last traded at ₹123.54, giving it a market capitalisation of ₹6,704 crore. The 52-week range is ₹33.05 to ₹150.7, and the price is 77% of the way up that range. It trades at a price-to-earnings ratio of 60.3. Promoters hold 35.66% of the company in the latest shareholding filing.
| Market cap | ₹6,704 crore |
|---|---|
| P/E | 60.3 |
| ROE | 5.3% |
| ROCE | 7.7% |